Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.

被引：26
|
作者：
Ciuleanu, T.
Samarzjia, M.
Demidchik, Y.
Beliakouski, V.
Rancic, M.
Bentsion, D. L.
Orlov, S. V.
Schaeffier, B. A.
De Jager, R. L.
Breitz, H. B.
机构：
[1] Inst Oncol I Chiricuta, Cluj Napoca, Romania
[2] Clin Pulm Dis, Zagreb, Croatia
[3] Minsk City Clin Oncol Dispensary, Minsk, BELARUS
[4] Gomel Reg Oncol Dispensary, Gomel, BELARUS
[5] Clin Ctr Nis, Nish, Serbia
[6] Sverdiovsk Reg Oncol Ctr, Ekaterinburg, Russia
[7] St Petersburg Pavlov State Med Univ, St Petersburg, Russia
[8] Poniard Pharmaceut Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7002
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR)
    Zhu, Andrew X.
    Chau, Ian
    Blanc, Jean-Frederic
    Okusaka, Takuji
    Rojas, Maria
    Yang, Ling
    Von Broen, Ingo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).
    Horn, Leora
    Reck, Martin
    Gettinger, Scott N.
    Spigel, David R.
    Antonia, Scott Joseph
    Rupnow, Brent A.
    Pieters, Anne
    Selvaggi, Giovanni
    Fairchild, Justin P.
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011
    Loriot, Yohann
    Balar, Arjun Vasant
    De Wit, Ronald
    Garcia, Jorge A.
    Grivas, Petros
    Matsubara, Nobuaki
    Moreno, Blanca Homet
    Sbar, Eric
    Jia, Xieyang Calvin
    Dutcus, Corina E.
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study
    Lenz, Heinz-Josef
    Tabernero, Josep
    Yoshino, Takayuki
    Lonardi, Sara
    Falcone, Alfredo
    Miron, Maria Luisa Limon
    Saunders, Mark P.
    Sobrero, Alberto F.
    Park, Young Suk
    Monteagudo, Reyes Ferreiro
    Hong, Yong Sang
    Tomasek, Jiri
    Taniguchi, Hiroya
    Ciardiello, Fortunato
    Sassi, Mouna
    Peil, Barbara
    Hastedt, Claudia
    Studeny, Matus
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [25] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies
    Hofheinz, R.
    Grothey, A.
    Sobrero, A. F.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. -J
    Yoshino, T.
    Cihon, F.
    Strauss, U. P.
    Van Cutsem, E.
    ONKOLOGIE, 2012, 35 : 255 - 255
  • [26] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
    Grothey, Axel
    Sobrero, Alberto F.
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Lenz, Heinz-Josef
    Yoshino, Takayuki
    Cihon, Frank
    Wagner, Andrea
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [27] A phase II study of picoplatin (pico) as second-line therapy for patients (pts) with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum (plat)-containing chemotherapy
    Bentzion, D.
    Lipatov, O.
    Polyakov, I.
    MacKintosh, R.
    Eckardt, J.
    Breitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage- SCLC: Results From the Phase 3 MERU Study
    Johnson, Melissa L.
    Zvirbule, Zanete
    Laktionov, Konstantin
    Helland, Aslaug
    Cho, Byoung Chul
    Gutierrez, Vanesa
    Colinet, Benoit
    Lena, Herve
    Wolf, Martin
    Gottfried, Maya
    Okamoto, Isamu
    van der Leest, Cor
    Rich, Patricia
    Hung, Jen-Yu
    Appenzeller, Christina
    Sun, Zhaowen
    Maag, David
    Luo, Yan
    Nickner, Caroline
    Vajikova, Alena
    Komarnitsky, Philip
    Bar, Jair
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1570 - 1581
  • [29] A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC).
    Komarnitsky, Philip B.
    Lee, Ho-Jin
    Shah, Manan
    Wong, Shekman
    Gauthier, Sanja
    Dziubinski, Juliann
    Osbaugh, Stacy
    Zhang, Fan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] A Phase 3, randomized study of first-line durvalumab (D) plus /- tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIAN
    Alt, J.
    Bischoff, H. G.
    Laack, H-E
    Leistner, R. D.
    Panse, J.
    Reinmuth, N.
    Schulz, C.
    Grohe, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 103 - 103
12345